McDermott and Bull executive Search
 

Other News

AliveCor and PulseAI Partner to Bring Advanced Cardiac AI Determinations and Clinical Care Platform to Major Consumer Wearables

FDA-cleared PulseAPI SmartWatch integration adds Premature Ventricular Contraction (PVC) detection to Apple Watch and cuts inconclusive ECG readings by 92%, easing clinical review burden PulseAI’s algorithmic engine also supports ECG rhythm determinations across Samsung, Withings, and Fitbit devices MOUNTAIN VIEW, Calif. & BELFAST, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, and PulseAI, a pioneer in artificial intelligence software for electrocardiogram (ECG) analysis, today announced a strategic partnership to expand clinical-grade cardiac care across mainstream consumer wearables. Leveraging PulseAI’s recent U.S. Food and Drug Administration (FDA) 510(k) clearance for PulseAPI SmartWatch, the collaboration will bring AI rhythm determinations to compatible third-party wearables for users with a KardiaCare subscription via the Kardia App. Most notably, the partnership will offer advanced detection of sinus rhythm with PVCs for Apple Watch customers. This new capability will seamlessly help convert personal wearable data into actionable clinical consultations and specialist overreads, helping close a long-standing gap in consumer wearable diagnostics. “Consumer wearables have successfully fostered personal wellness, but the real breakthrough lies in turning daily tracking into clinically actionable data,” said Priya Abani, CEO of AliveCor. “Heart disease remains the leading global health challenge, and by democratizing access to medical-grade insights and cardiovascular specialists at scale, we can detect conditions earlier, improve outcomes, and save more lives.” “We are excited to announce our first partnership for our AI ECG technology,” said Dr Alan Kennedy, CEO of PulseAI. “Our mission is to make advanced ECG analysis accessible to as many patients as possible. Partnering with AliveCor brings us closer to that goal by connecting the wearable devices people already use with meaningful heart rhythm insights and clinical care.” Clinical-Grade AI for Leading WearablesThe PulseAPI SmartWatch platform acts as an intelligent software library that processes and analyzes Lead I data from compatible wearable devices. Under the FDA clearance, the algorithms deliver automated noise filtering, heart rate measurement, and targeted rhythm classification: Advanced Capabilities for Apple Watch Users: When processing Lead I data from compatible Apple Watch hardware, the platform delivers rhythm analysis for sinus rhythm, atrial fibrillation (AFib), bradycardia, and tachycardia. Critically, it provides beat-by-beat QRS detection to identify normal sinus rhythm versus sinus rhythm with PVCs, classifies individual beats as sinus rhythm with PVC or non-PVC.Broad Consumer Ecosystem Support: PulseAI’s FDA-cleared algorithmic engine supports ECG rhythm determinations (detecting sinus rhythm, AFib, noisy recordings, and average beat calculation) across leading consumer wearables and monitors, including Samsung Galaxy Watch, Fitbit Sense, and Withings ScanWatch. While consumer wearables have traditionally alerted users to basic rhythm abnormalities, this partnership transforms isolated data into meaningful context for healthcare providers. In Apple Watch, beyond expanding rhythm classifications, the technology directly tackles one of the largest bottlenecks in digital cardiology: the administrative and clinical burden created by inconclusive ECGs, which often trigger manual reviews, repeat recordings, and unnecessary follow-ups. In a prospective study of 296 participants published in Heart Rhythm, PulseAI’s algorithm improved AFib detection sensitivity while delivering a 92% reduction in inconclusive interpretations compared to the Apple Watch’s native algorithm—enabling clinical teams to manage higher recording volumes with existing resources. Advanced determinations from the AliveCor and PulseAi partnership will be available on select, compatible third-party devices including Apple Watch, Samsung Galaxy Watch, Fitbit Sense, and Withings ScanWatch in the first half of 2027. For more information contact press@alivecor.com. About AliveCorAliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the TIME World’s Top HealthTech Companies list for the second consecutive year in 2026—recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 400 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook. About PulseAI PulseAI, founded in 2020, is based in Belfast, Northern Ireland. The company has developed deep learning algorithms trained on millions of ECGs to deliver clinically validated performance across smartwatches, patches, hospital monitors, and defibrillators. For more information, visit www.pulseai.io and follow us on LinkedIn and X (Twitter). Media Contacts Alivecor Morgan MathisDirector of Corporate Communications, AliveCorpress@alivecor.com Pulse AIAlan KennedyCEO and Founder, PulseAIalan.kennedy@pulseai.io

Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel

– Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel. DURHAM, N.C., Nov. 16, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced new results showing that its acellular tissue engineered vessel (ATEV) were observed to have low susceptibility to atherosclerosis in patients over multiple years of implantation. The findings were presented at the 2026 ISVTE-ISACB Joint Meeting in Miami, a leading scientific meeting for vascular tissue engineering that brings together the field’s major academic laboratories and companies. “Atherosclerosis is one of the long-term threats to any vascular graft. Until now there has been no long-term clinical evidence on how bioengineered vessels hold up against it,” said Juan Wang, Ph.D., Principal Scientist at Humacyte, who presented the findings. “Across more than 50 patients, many with significant cardiovascular risk factors, we saw very little evidence of the disease taking hold in the ATEV, even years after implantation. We believe that these results support the long-term durability of the ATEV as a potential option for vascular surgeons to use in the operating room.” Certain conventional vascular grafts, including a patient’s own vessels, synthetic grafts, and animal-derived tissues, are known to carry a risk of atherosclerosis, which can potentially compromise their long-term performance. In the presentation, titled “Long-Term Clinical Evidence of Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Blood Vessels,” Humacyte scientists analyzed ATEV tissue from 52 patients who received the ATEV for arteriovenous (AV) access in hemodialysis or for peripheral artery bypass across five clinical trials. Implant durations ranged from less than one week to more than five years. “Durability is one of the most important questions surgeons ask about any vascular conduit,” added Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. “This data, drawn from patients implanted for as long as five years, suggest that the ATEV’s biology works over time. That matters as we work to bring the ATEV to more patients including, if approved by the FDA, those who need long-term reliable access for hemodialysis.” Despite a high prevalence of atherosclerosis risk factors in the patient population, the research showed: Minimal lipid deposition (an average of only 0.6% of tissue area) and scarce foam cell formation, both of which are indicators of early atherosclerotic plaque development.Inflammatory cells, including macrophages, were largely absent from the ATEV wall.Over 95% of ATEV explants evaluated showed no or only a minor presence of early markers for atherosclerosis, even after more than five years of implantation.Only 4.7% of ATEVs studied showed some atypical fatty streaks and none showed evidence of vulnerable plaques.Consistent with previous findings, the ATEVs were progressively repopulated with the patient’s own smooth muscle and endothelial cells and adaptively remodeled. The researchers attribute the ATEV’s low susceptibility to atherosclerosis to its acellular, biocompatible composition, and low innate proteoglycan content which may support non-inflammatory repopulation by the patient’s own cells and limit the retention of the lipids and lipoproteins that drive plaque formation. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. About Humacyte Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com. Forward-Looking Statements This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our plans, anticipated timeline and ability to file applications for, and obtain marketing approvals from, the FDA and other regulatory authorities, including the European Medicines Agency, for our ATEVs and product candidates; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding the results of our clinical trials, and regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs and the public perception thereof; the implementation of our business model and strategic plans for our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended September 30, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Humacyte Investor Contact:Joyce AllaireLifeSci Advisors LLC+1-617-435-6602jallaire@lifesciadvisors.cominvestors@humacyte.com Humacyte Media Contact:Rich LuchettePrecision Strategies+1-202-845-3924rich@precisionstrategies.commedia@humacyte.com

Adagio Medical Reports Third Quarter 2026 Results

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026. Recent Business Highlights: Ultra-Low temperature ablation (“ULTA”) featured in four podium presentations at the VT Symposium 2026 held October 9-10 in New York, with topics spanning clinical experience, comp

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results

Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020 generally well tolerated across 10 participants with no clinically significant complement activation U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC), as well as improvement in measures of right ventricular function and patient-reported symptoms. Lexeo is now designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval. The final study design including the statistical analysis plan and confirmatory strategy remains subject to future discussions with the FDA. “These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM. Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.” “For families living with PKP2 arrhythmogenic cardiomyopathy, the risks and uncertainties reach far beyond the clinic and into every part of daily life,” said Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias (FIA). “Our community has waited a long time for treatments that might address the underlying cause of this disease. Early results like these give ACM families reason to hope for better, more targeted care. We look forward to larger studies that build on these findings.” LX2020 Interim UpdateTen participants have been dosed in the HEROIC-PKP2 Phase I/II clinical trial, including three participants in Cohort 1 at the low dose (2×1013 vg/kg) and seven participants in Cohorts 2 and 3 at the high dose (6×1013 vg/kg). As of the October 15, 2026 data cutoff date, nine of ten participants reached at least 12 months of follow-up, with the remaining participant reaching nine months of follow-up. Safety and efficacy data are summarized for all ten participants at latest assessment. Clinical Data 80% mean reduction in NSVT at latest assessment relative to baseline in high-dose cohorts (n=7), with deepening reduction in mean NSVT burden over time; six of seven participants demonstrated improvement at latest assessment44% mean reduction in PVC burden at latest assessment relative to baseline in high-dose cohorts (n=7); five of seven participants demonstrated improvement at latest assessmentFive of seven participants in high-dose cohorts reported symptom improvement at latest visit relative to baseline on the Patient Global Impression of Change (PGIC) scale, a patient-reported outcome measurePreliminary evidence of stabilization or improvement in cardiac function assessed by cardiac MRI in the majority of participants in high-dose cohortsCardiac biopsy findings demonstrated dose-dependent increases in LX2020 transduction, mean exogenous PKP2 mRNA expression and mean PKP2 protein expression Safety LX2020 generally well tolerated across ten participants dosedNo clinically significant complement activation was observed and no participant discontinued the studyPreviously disclosed elevations in liver function tests (LFT) were observed in the high-dose cohorts and were treated successfully per the trial protocol with no complications or hospitalizationsOne previously disclosed Grade 3 serious adverse event of ventricular tachycardia (VT) was observed three months after dosing. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required Regulatory Update and Next Steps The FDA is open to use of guideline-defined NSVT as a primary surrogate endpoint in an accelerated approval pivotal studyFinalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027 Q3 2026 Earnings UpdateToday, Lexeo also reported financial results for the third quarter of 2026: Cash Position: As of September 30, 2026, cash, cash equivalents, and investments in marketable securities were $219.1 million, which Lexeo believes will be sufficient to fund operations into 2028Research & Development Expenses: Research and Development expenses were $34.5 million for the three months ended September 30, 2026, compared to $15.7 million for the three months ended September 30, 2025. The majority of the increase was driven by one-time costs including the acquisition of Mantle Therapeutics, which closed in September 2026, as well as a development milestone that was achieved in the third quarter of 2026 related to LX2006 pivotal study initiationGeneral & Administrative Expenses: General and Administrative expenses were $5.9 million for the three months ended September 30, 2026, compared to $6.0 million for the three months ended September 30, 2025Net Loss: Net loss was $38.3 million or $0.43 per share (basic and diluted) for the three months ended September 30, 2026, compared to $20.3 million or $0.33 per share (basic and diluted) for the three months ended September 30, 2025 Lexeo also announced the appointment of Toby Schilke as an independent director to the Board of Directors. Most recently, Mr. Schilke served as Chief Financial Officer of Crinetics Pharmaceuticals. He previously served as Chief Financial Officer at Revance Therapeutics and Achaogen. Earlier in his career, he held leadership roles across corporate development, commercial finance, marketing, and global operations at Roche and Genentech. Corporate Webcast DetailsLexeo Therapeutics will host a webcast at 8:00 AM ET today, November 16, 2026. Analysts and investors can participate by accessing the webcast live on the Events & Presentations page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call. About LX2020 LX2020 is an AAV-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM). Mutations in the PKP2 gene are the most common genetic cause of ACM, responsible for approximately 50% of cases and estimated to affect approximately 60,000 people in the United States. PKP2 deficiency in ACM can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities, and sudden cardiac death. LX2020 is designed to systemically deliver a functional, full-length PKP2 gene within an adeno-associated viral capsid, AAVrh10, to cardiomyocytes to restore the desmosomal complex and cell-to-cell adhesion. LX2020 is being evaluated in the single-arm, open-label, multi-center HEROIC-PKP2 Phase I/II clinical trial (NCT06109181). LX2020 has been granted Regenerative Medicine Advanced Therapy, Orphan Drug and Fast Track designations by the FDA. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need. Cautionary Note Regarding Forward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs and the anticipated benefits of its current product candidates, the timing and likelihood of potential regulatory developments, trial design changes and approval, and expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs, including the outcome of ongoing discussions with the FDA regarding the design of the pivotal study to support an application for accelerated approval of LX2020, statistical analysis plan and confirmatory evidence strategy; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Media Response:Media@lexeotx.com Investor Response:Investors@lexeotx.com Lexeo Therapeutics, Inc.Selected Financial Information(Unaudited, in thousands, except share and per share amounts)Statements of Operations     Three Months Ended September 30, Nine Months Ended September 30,  2026   2025   2026   2025 Operating expenses       Research and development$34,496  $15,695  $69,226  $47,587 General and administrative 5,903   5,953   21,526   38,554 Total operating expenses 40,399   21,648   90,752   86,141 Operating loss (40,399)  (21,648)  (90,752)  (86,141)Other income and expense       Gain on long-term investment –   –   –   3,390 Other expense, net (9)  (9)  (16)  (27)Interest expense (12)  (22)  (43)  (75)Interest income 2,160   1,456   6,467   3,917 Amortization of premium on investments in U.S. Treasury securities, net (40)  (60)  (19)  (106)Total other income and expense 2,099   1,365   6,389   7,099 Loss from operations before income taxes (38,300)  (20,283)  (84,363)  (79,042)Income taxes –   –   –   – Net loss$(38,300) $(20,283) $(84,363) $(79,042)Net loss per common share, basic and diluted$(0.43) $(0.33) $(0.99) $(1.72)Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted 88,681,360   60,980,867   85,191,438   45,991,572  Balance Sheet Data       September 30, December 31,   2026  2025Cash, cash equivalents, and investments in U.S. Treasury securities $219,134 $246,568Total assets  243,916  268,688Total liabilities  27,225  22,019Total stockholders’ equity  216,691  246,669

Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology

KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated 100% all-shock conversion success and sustained daily wear, while documenting ventricular arrhythmias early and continuously over subsequent months. The findings strengthen the clinical case for the ASSURE system across WCD indications and underscore the importance of protecting patients throughout periods of elevated arrhythmic risk. “Advances in medical therapy have improved cardiac recovery after a myocardial infarction or a new heart failure diagnosis, but the recovery period can leave patients vulnerable to life-threatening ventricular arrhythmias,” said Jeanne E. Poole, MD, Professor of Medicine at the University of Washington and Principal Investigator. “ACE-PAS confirmed the early risk of ventricular tachycardia and ventricular fibrillation (VT/VF) and demonstrates why WCD protection matters: it provides an opportunity to prevent sudden cardiac death while giving patients time to recover.” The publication provides a full report of findings first presented as late-breaking science at the American Heart Association Scientific Sessions 2025, along with additional analyses of arrhythmic risk. Key findings include: 100% all-shock conversion   ASSURE WCD successfully converted all 303 analyzable VT/VF shock events with one or more shocks, meeting the primary effectiveness endpoint.  Primary safety endpoint achieved  The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal. 94% of patients experienced no false-positive shock alarms The low alarm burden supports a better patient experience and helps enable the sustained wear needed for continuous protection. 23.1 hours of median daily wear—even beyond 90 days Patients wore ASSURE for a median of 23.1 hours per day.30% continued use beyond 90 days while maintaining the same median daily wear time, highlighting ASSURE’s practicality in real-world, long-term care. VT/VF risk persisted beyond the first month 2.6% of patients experienced at least one shocked or unshocked VT/VF event. While 55% of episodes occurred during the first month, events continued in subsequent months—reinforcing the need for protection throughout the prescription period. Meaningful arrhythmic risk extended across major etiologies Among patients with LVEF ≤35% who met primary-prevention criteria for sudden cardiac death, the estimated risk of experiencing VT/VF within 90 days was 3.2% following myocardial infarction, 2.8% in ischemic cardiomyopathy and 2.5% in nonischemic cardiomyopathy.   “Publication of the ACE-PAS results marks an important milestone in advancing the evidence base for wearable defibrillator therapy and monitoring,” said Brian Webster, President and CEO of Kestra Medical Technologies. “Real-world evidence at this scale reinforces confidence in the ASSURE system and strengthens the clinical foundation for protecting patients during recovery. We will continue to build on these insights to give providers more ways to protect at risk patients.” Drawing on ACE-PAS data, Kestra introduced an enhanced detection algorithm in April 2026 for the ASSURE WCD that further reduces the already low false-positive alarm burden while maintaining VT/VF detection sensitivity. With the enhanced algorithm, the inappropriate shock rate is projected to decrease by nearly 70%, from 0.0065 to 0.0020 per patient-month.1, 2 The peer-reviewed publication, “Real-World Performance of a Novel Wearable Cardioverter-Defibrillator System: Primary Results From a National Prospective Post-Approval Registry Study (ACE-PAS),” is available at http://doi.org/10.1111/jce.70556 About ACE-PASThe ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) was an FDA-mandated, prospective, single-arm post-approval registry evaluating the safety and effectiveness of the ASSURE Wearable Cardioverter Defibrillator in routine clinical use. Funded by Kestra, the study included 21,612 patients fitted between November 2021 and July 2025. Primary endpoints were all-shock VT/VF conversion success and inappropriate-shock incidence, evaluated against prespecified performance goals. About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.  Forward-Looking StatementsThis press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. For a discussion of factors that could cause actual results to differ, see Kestra’s filings with the U.S. Securities and Exchange Commission. Kestra undertakes no obligation to update any forward-looking statements except as required by law. Finch D, et al. Research Square. April 22, 2026. Preprint.Poole JE, et al. Circulation. 2025;152:e526–e605. CONTACT: Media contact 
Rhiannon Pickus 
rhiannon.pickus@kestramedical.com 

Investor contact 
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com 

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR). Session details are as follows:Session: TAVI Hotline – Part 1Track: Hotline / Late-Breaking TrialsDate and time: Sunday, November 22, 2026, 9:30 AM – 10:30 AM GMT/UTC+0Location: Dubai RoomTitle: One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic AnnuliPresenter: Rishi Puri, MD, PhD, Cleveland Clinic About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. For more information:   Global Investor RelationsInvestor Relations (US)investors@anteristech.commchatterjee@bplifescience.comDebbie OrmsbyMalini Chatterjee, Ph.D.Anteris Technologies Global Corp.Blueprint Life Science Group+61 1300 550 310 | +61 7 3152 3200+1 917 330 4269   Websitewww.anteristech.comX@AnterisTechLinkedInhttps://www.linkedin.com/company/anteristech

Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM

MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO® (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms. “People living with HCM deserve treatment decisions grounded in rigorous evidence. For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In MAPLE-HCM, MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden and cardiac biomarkers compared to metoprolol. MYQORZO is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its U.S. label, providing cardiologists and patients important information to inform treatment decisions.” MYQORZO was approved by the FDA in December 2025 for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms based on the results from SEQUOIA-HCM, the pivotal, randomized, placebo-controlled, Phase 3 clinical trial of MYQORZO in patients with oHCM on background therapy. It is also approved for the treatment of patients with oHCM in China, European Union, United Kingdom and Canada. The full U.S. Prescribing Information for MYQORZO includes a Boxed WARNING for the risk of heart failure. MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients LVEF